Annual D&A
$38.53 M
+$17.81 M+85.96%
December 31, 2023
Summary
- As of February 12, 2025, TVTX annual depreciation & amortization is $38.53 million, with the most recent change of +$17.81 million (+85.96%) on December 31, 2023.
- During the last 3 years, TVTX annual D&A has risen by +$13.95 million (+56.76%).
- TVTX annual D&A is now at all-time high.
Performance
TVTX Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
Quarterly D&A
$11.24 M
+$894.00 K+8.64%
September 30, 2024
Summary
- As of February 12, 2025, TVTX quarterly depreciation & amortization is $11.24 million, with the most recent change of +$894.00 thousand (+8.64%) on September 30, 2024.
- Over the past year, TVTX quarterly D&A has increased by +$1.75 million (+18.45%).
- TVTX quarterly D&A is now -2.06% below its all-time high of $11.47 million, reached on September 30, 2023.
Performance
TVTX Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM D&A
$40.95 M
-$236.00 K-0.57%
September 30, 2024
Summary
- As of February 12, 2025, TVTX TTM depreciation & amortization is $40.95 million, with the most recent change of -$236.00 thousand (-0.57%) on September 30, 2024.
- Over the past year, TVTX TTM D&A has increased by +$2.42 million (+6.29%).
- TVTX TTM D&A is now -2.01% below its all-time high of $41.79 million, reached on March 31, 2024.
Performance
TVTX TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TVTX Depreciation And Amortization Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +86.0% | +18.4% | +6.3% |
| 3 y3 years | +56.8% | +78.1% | +97.7% |
| 5 y5 years | +106.4% | +78.1% | +97.7% |
TVTX Depreciation And Amortization Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +202.3% | -2.1% | +243.7% | -2.0% | +521.8% |
| 5 y | 5-year | at high | +202.3% | -2.1% | +243.7% | -2.0% | +521.8% |
| alltime | all time | at high | >+9999.0% | -2.1% | +243.7% | -2.0% | >+9999.0% |
Travere Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $11.24 M(+8.6%) | $40.95 M(-0.6%) |
| Jun 2024 | - | $10.35 M(+4.7%) | $41.19 M(-1.4%) |
| Mar 2024 | - | $9.88 M(+4.1%) | $41.79 M(+8.5%) |
| Dec 2023 | $38.53 M(+86.0%) | $9.49 M(-17.3%) | $38.53 M(+9.0%) |
| Sep 2023 | - | $11.47 M(+4.8%) | $35.35 M(+53.1%) |
| Jun 2023 | - | $10.95 M(+65.4%) | $23.09 M(+14.0%) |
| Mar 2023 | - | $6.62 M(+4.9%) | $20.25 M(-2.3%) |
| Dec 2022 | $20.72 M(+62.6%) | $6.31 M(-896.0%) | $20.72 M(+214.6%) |
| Sep 2022 | - | -$793.00 K(-109.8%) | $6.59 M(-56.8%) |
| Jun 2022 | - | $8.11 M(+14.3%) | $15.25 M(+10.8%) |
| Mar 2022 | - | $7.09 M(-190.7%) | $13.76 M(+8.0%) |
| Dec 2021 | $12.75 M(-48.1%) | -$7.82 M(-199.3%) | $12.75 M(-53.1%) |
| Sep 2021 | - | $7.87 M(+18.9%) | $27.20 M(+5.6%) |
| Jun 2021 | - | $6.62 M(+9.0%) | $25.77 M(+3.1%) |
| Mar 2021 | - | $6.07 M(-8.4%) | $25.00 M(+1.7%) |
| Dec 2020 | $24.58 M(+20.4%) | $6.63 M(+3.0%) | $24.58 M(+5.8%) |
| Sep 2020 | - | $6.44 M(+10.0%) | $23.24 M(+4.8%) |
| Jun 2020 | - | $5.85 M(+3.4%) | $22.17 M(+4.8%) |
| Mar 2020 | - | $5.66 M(+6.9%) | $21.16 M(+3.7%) |
| Dec 2019 | $20.41 M(+9.3%) | $5.29 M(-1.6%) | $20.41 M(+2.1%) |
| Sep 2019 | - | $5.38 M(+11.1%) | $20.00 M(+3.0%) |
| Jun 2019 | - | $4.84 M(-1.2%) | $19.42 M(+1.0%) |
| Mar 2019 | - | $4.90 M(+0.5%) | $19.22 M(+3.0%) |
| Dec 2018 | $18.67 M | $4.88 M(+1.7%) | $18.67 M(+2.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $4.80 M(+3.3%) | $18.26 M(+1.0%) |
| Jun 2018 | - | $4.64 M(+6.8%) | $18.07 M(+1.2%) |
| Mar 2018 | - | $4.35 M(-2.7%) | $17.87 M(+0.4%) |
| Dec 2017 | $17.80 M(+10.3%) | $4.47 M(-3.2%) | $17.80 M(+1.6%) |
| Sep 2017 | - | $4.62 M(+4.0%) | $17.52 M(+3.1%) |
| Jun 2017 | - | $4.44 M(+3.6%) | $17.00 M(+2.8%) |
| Mar 2017 | - | $4.28 M(+2.4%) | $16.53 M(+2.4%) |
| Dec 2016 | $16.14 M(+20.5%) | $4.18 M(+2.1%) | $16.14 M(+1.3%) |
| Sep 2016 | - | $4.09 M(+3.2%) | $15.93 M(+1.4%) |
| Jun 2016 | - | $3.97 M(+2.0%) | $15.71 M(+1.4%) |
| Mar 2016 | - | $3.89 M(-2.1%) | $15.50 M(+15.8%) |
| Dec 2015 | $13.39 M(+148.0%) | $3.98 M(+2.4%) | $13.39 M(+18.8%) |
| Sep 2015 | - | $3.88 M(+3.3%) | $11.28 M(+22.0%) |
| Jun 2015 | - | $3.76 M(+111.2%) | $9.24 M(+31.1%) |
| Mar 2015 | - | $1.78 M(-4.3%) | $7.05 M(+30.6%) |
| Dec 2014 | $5.40 M(+2400.5%) | $1.86 M(+0.4%) | $5.40 M(+50.0%) |
| Sep 2014 | - | $1.85 M(+18.2%) | $3.60 M(+99.6%) |
| Jun 2014 | - | $1.57 M(+1131.0%) | $1.80 M(+519.8%) |
| Mar 2014 | - | $127.20 K(+123.6%) | $291.00 K(+34.7%) |
| Dec 2013 | $216.00 K(+72.9%) | $56.90 K(+5.8%) | $216.00 K(+35.8%) |
| Sep 2013 | - | $53.80 K(+1.3%) | $159.10 K(+51.1%) |
| Jun 2013 | - | $53.10 K(+1.7%) | $105.30 K(+101.7%) |
| Mar 2013 | - | $52.20 K | $52.20 K |
| Dec 2012 | $124.90 K | - | - |
FAQ
- What is Travere Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Travere Therapeutics?
- What is Travere Therapeutics annual D&A year-on-year change?
- What is Travere Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Travere Therapeutics?
- What is Travere Therapeutics quarterly D&A year-on-year change?
- What is Travere Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Travere Therapeutics?
- What is Travere Therapeutics TTM D&A year-on-year change?
What is Travere Therapeutics annual depreciation & amortization?
The current annual D&A of TVTX is $38.53 M
What is the all time high annual D&A for Travere Therapeutics?
Travere Therapeutics all-time high annual depreciation & amortization is $38.53 M
What is Travere Therapeutics annual D&A year-on-year change?
Over the past year, TVTX annual depreciation & amortization has changed by +$17.81 M (+85.96%)
What is Travere Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of TVTX is $11.24 M
What is the all time high quarterly D&A for Travere Therapeutics?
Travere Therapeutics all-time high quarterly depreciation & amortization is $11.47 M
What is Travere Therapeutics quarterly D&A year-on-year change?
Over the past year, TVTX quarterly depreciation & amortization has changed by +$1.75 M (+18.45%)
What is Travere Therapeutics TTM depreciation & amortization?
The current TTM D&A of TVTX is $40.95 M
What is the all time high TTM D&A for Travere Therapeutics?
Travere Therapeutics all-time high TTM depreciation & amortization is $41.79 M
What is Travere Therapeutics TTM D&A year-on-year change?
Over the past year, TVTX TTM depreciation & amortization has changed by +$2.42 M (+6.29%)